


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-5 (Cancelled).

6. (New): A compound of formula (i) or a pharmaceutically acceptable salt thereof:



wherein

$R^1$  and  $R^2$  independently represent hydrogen or  $C_{1-6}$  alkyl;

$p$  represents 1 or 2;

$m$  represents an integer from 1 to 4;

$R^3$  represents hydrogen, halogen, cyano,  $-CF_3$ ,  $-OCF_3$ ,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkanoyl or a group  $-CONR^6R^7$ ;

$R^{3a}$  and  $R^5$  independently represent hydrogen or  $C_{1-6}$  alkyl;


$R^6$  and  $R^7$  independently represent hydrogen or  $C_{1-6}$  alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

$n$  represents 1 or 2; and

$A$  represents a phenyl or pyridyl group optionally substituted by one or more halogen atoms, cyano, trifluoromethyl or trifluoromethoxy;

or solvates thereof.

7. (New): A compound of formula (ii) or a pharmaceutically acceptable salt thereof:



(ii)

wherein

$R^1$  and  $R^2$  independently represent hydrogen or  $C_{1-6}$  alkyl;

$p$  represents 1 or 2;

$m$  represents an integer from 1 to 4;

$R^3$  represents hydrogen, halogen, cyano,  $-CF_3$ ,  $-OCF_3$ ,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkanoyl or a group  $-CONR^6R^7$ ;

$R^{3a}$  and  $R^5$  independently represent hydrogen or  $C_{1-6}$  alkyl;


$R^6$  and  $R^7$  independently represent hydrogen or  $C_{1-6}$  alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

$n$  represents 1 or 2; and

$A$  represents a phenyl or pyridyl group optionally substituted by one or more halogen atoms, cyano, trifluoromethyl or trifluoromethoxy;

or solvates thereof.

8. (New): A compound of formula (iii) or a pharmaceutically acceptable salt thereof:



(iii)

wherein

$R^1$  and  $R^2$  independently represent hydrogen or  $C_{1-6}$  alkyl;

$p$  represents 1 or 2;

$m$  represents an integer from 1 to 4;

$R^3$  and  $R^4$  independently represent hydrogen, halogen, cyano,  $-CF_3$ ,  $-OCF_3$ ,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkanoyl or a group  $-CONR^6R^7$ ;


$R^6$  and  $R^7$  independently represent hydrogen or  $C_{1-6}$  alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

$n$  represents 1 or 2;

$s$  represents an integer from 1 to 3; and

A represents a phenyl or pyridyl group optionally substituted by one or more halogen atoms, cyano, trifluoromethyl or trifluoromethoxy;  
or solvates thereof.

9. (New): A compound of formula (iv) or a pharmaceutically acceptable salt thereof:



(iv)

wherein

R<sup>1</sup> and R<sup>2</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl;

p represents 1 or 2;

m represents an integer from 1 to 4;

R<sup>3</sup> and R<sup>4</sup> independently represent hydrogen, halogen, cyano, -CF<sub>3</sub>, -OCF<sub>3</sub>, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkanoyl or a group -CONR<sup>6</sup>R<sup>7</sup>;

R<sup>6</sup> and R<sup>7</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

q represents 1 or 2;

r represents an integer from 1 to 3; and

A represents a phenyl or pyridyl group optionally substituted by one or more halogen atoms, cyano, trifluoromethyl or trifluoromethoxy;

or solvates thereof.

10. (New): A compound according to claim 6 which is:

4-(3-Phenylsulfonyl-1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)-piperazine hydrochloride;

4-Methyl-7-piperazin-1-yl-3-phenylsulfonyl-4*H*-pyrrolo[3,2-*b*] pyridine;

1-Methyl-7-piperazin-1-yl-3-phenylsulfonyl-1*H*-pyrrolo[3,2-*b*] pyridine;

1-Methyl-7-piperazin-1-yl-3-(2-fluorophenyl)sulfonyl-1*H*-pyrrolo[3,2-*b*] pyridine;

4-Methyl-7-piperazin-1-yl-3-(2-fluorophenyl)sulfonyl-4*H*-pyrrolo[3,2-*b*] pyridine;

or a pharmaceutically acceptable salt thereof.

11. (New): A compound according to claim 7 which is:

7-Piperazin-1-yl-3-phenylsulfonyl-1*H*-pyrrolo[2,3-*c*] pyridine hydrochloride;

3-(2-Fluorophenyl)sulfonyl-7-piperazin-1-yl-1*H*-pyrrolo[2,3-*c*]pyridine hydrochloride;

3-(3-Fluorophenyl)sulfonyl-7-piperazin-1-yl-1*H*-pyrrolo[2,3-*c*]pyridine hydrochloride;

or a pharmaceutically acceptable salt thereof.

12. (New): A compound according to claim 8 which is:

2-Methyl-4-piperazin-1-yl-7-phenylsulfonylquinoline hydrochloride;

or a pharmaceutically acceptable salt thereof.

13. (New): A compound according to claim 9 which is:

4-Phenylsulfonyl-8-piperazin-1-yl quinoline;

4-Phenylsulfonyl-8-piperazin-1-yl-quinoline hydrochloride;

2-Methyl -4-phenylsulfonyl-8-piperazin-1-yl-quinoline;

2-Methyl-4-phenylsulfonyl-8-piperazin-1-ylquinoline hydrochloride;

2-Methyl-4-(2-fluorophenyl)sulfonyl-8-piperazin-1-ylquinoline hydrochloride;

2-Methyl-4-(3-fluorophenyl)sulfonyl-8-piperazin-1-ylquinoline hydrochloride;

2-Methyl-4-(3-chlorophenyl)sulfonyl-8-piperazin-1-ylquinoline hydrochloride;

or a pharmaceutically acceptable salt thereof.

14. (New): A pharmaceutical composition which comprises a compound according to claim 6 and a pharmaceutically acceptable carrier or excipient.

15. (New): A pharmaceutical composition which comprises a compound according to claim 7 and a pharmaceutically acceptable carrier or excipient.

16. (New): A pharmaceutical composition which comprises a compound according to claim 8 and a pharmaceutically acceptable carrier or excipient.

17. (New): A pharmaceutical composition which comprises a compound according to claim 9 and a pharmaceutically acceptable carrier or excipient.

18. (New): A method of treating depression, anxiety, obesity and cognitive memory disorders which comprises administering a safe and therapeutically effective amount to a patient in need thereof of a compound as defined in claim 6 or a pharmaceutically acceptable salt thereof.

19. (New): A method of treating depression, anxiety, obesity and cognitive memory disorders which comprises administering a safe and therapeutically effective amount to a patient in need thereof of a compound as defined in claim 7 or a pharmaceutically acceptable salt thereof.

20. (New): A method of treating depression, anxiety, obesity and cognitive memory disorders which comprises administering a safe and therapeutically effective amount to a patient in need thereof of a compound as defined in claim 8 or a pharmaceutically acceptable salt thereof.

21. (New): A method of treating depression, anxiety, obesity and cognitive memory disorders which comprises administering a safe and therapeutically effective amount to a patient in need thereof of a compound as defined in claim 9 or a pharmaceutically acceptable salt thereof.